Company attributes
Other attributes
Codagenix is a privately held, biotechnology company based in Stony Brook, New York. The company focuses on constructing live-attenuated viral vaccines against multiple targets using the company's proprietary technology platform, SAVE. Standing for Synthetic Attenuated Virus Engineering, the platform relies on synthetic biology and the rational 're-design' of a target virus' entire genome to yield a vaccine strain. The customization process uses software-based algorithms to 're-code' the genome of a target virus.
The company's product pipeline includes vaccines for influenza, respiratory syncytial virus (RSV), dengue, foot and mouth disease virus (FMDV), pathogenic E. Coli, and other targets.
In February 2020, the company teamed up with the Serum Institute of India to co-develop a live-attenuated vaccine for COVID-19. The company uses viral deoptimization technology in order to create multiple vaccine candidates for a virus.
